Literature DB >> 24366691

Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.

Carlos Rodrigo Gil del Alcazar1, Molly Catherine Hardebeck, Bipasha Mukherjee, Nozomi Tomimatsu, Xiaohuan Gao, Jingsheng Yan, Xian-Jin Xie, Robert Bachoo, Li Li, Amyn A Habib, Sandeep Burma.   

Abstract

PURPOSE: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors. Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro. Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in vivo and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. EXPERIMENTAL
DESIGN: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and orthotopic glioblastoma models. Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth.
RESULTS: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma.
CONCLUSIONS: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366691      PMCID: PMC3947495          DOI: 10.1158/1078-0432.CCR-13-1607

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice.

Authors:  M Yamaguchi; H Saito; M Suzuki; K Mori
Journal:  Neuroreport       Date:  2000-06-26       Impact factor: 1.837

2.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Authors:  W P Roos; L F Z Batista; S C Naumann; W Wick; M Weller; C F M Menck; B Kaina
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

3.  Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.

Authors:  Y Sonoda; T Ozawa; Y Hirose; K D Aldape; M McMahon; M S Berger; R O Pieper
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

4.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

5.  DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs.

Authors:  Eric T Shinohara; Ling Geng; Jiahui Tan; Heidi Chen; Yu Shir; Eric Edwards; James Halbrook; Edward A Kesicki; Adam Kashishian; Dennis E Hallahan
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 6.  Emerging molecular mechanisms of brain tumour oedema.

Authors:  M C Papadopoulos; S Saadoun; D C Davies; B A Bell
Journal:  Br J Neurosurg       Date:  2001-04       Impact factor: 1.596

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 8.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.

Authors:  Bernd Kaina; Markus Christmann; Steffen Naumann; Wynand P Roos
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Loss of the catalytic subunit of the DNA-dependent protein kinase in DNA double-strand-break-repair mutant mammalian cells.

Authors:  S R Peterson; A Kurimasa; M Oshimura; W S Dynan; E M Bradbury; D J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

10.  Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Authors:  Yan Zhao; Huw D Thomas; Michael A Batey; Ian G Cowell; Caroline J Richardson; Roger J Griffin; A Hilary Calvert; David R Newell; Graeme C M Smith; Nicola J Curtin
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

View more
  68 in total

Review 1.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

2.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.

Authors:  Robert J G Cardnell; Carmen Behrens; Lixia Diao; YouHong Fan; Ximing Tang; Pan Tong; John D Minna; Gordon B Mills; John V Heymach; Ignacio I Wistuba; Jing Wang; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

4.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Authors:  Andrew J Leiker; William DeGraff; Rajani Choudhuri; Anastasia L Sowers; Angela Thetford; John A Cook; Carter Van Waes; James B Mitchell
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

5.  Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.

Authors:  Carlos Rodrigo Gil Del Alcazar; Pavlina Krasimirova Todorova; Amyn A Habib; Bipasha Mukherjee; Sandeep Burma
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

6.  Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.

Authors:  Yulia V Surovtseva; Vikram Jairam; Ahmed F Salem; Ranjini K Sundaram; Ranjit S Bindra; Seth B Herzon
Journal:  J Am Chem Soc       Date:  2016-03-09       Impact factor: 15.419

7.  Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.

Authors:  Amanda R King; Christopher D Corso; Evan M Chen; Eric Song; Paul Bongiorni; Zhe Chen; Ranjini K Sundaram; Ranjit S Bindra; W Mark Saltzman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

8.  MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Authors:  Shaofang Wu; Shuzhen Wang; Siyuan Zheng; Roel Verhaak; Dimpy Koul; W K Alfred Yung
Journal:  Mol Cancer Ther       Date:  2016-04-22       Impact factor: 6.261

Review 9.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

10.  Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair.

Authors:  Durga Udayakumar; Raj K Pandita; Nobuo Horikoshi; Yan Liu; Qingsong Liu; Kwok-Kin Wong; Clayton R Hunt; Nathanael S Gray; John D Minna; Tej K Pandita; Kenneth D Westover
Journal:  Radiat Res       Date:  2016-05-02       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.